Highest-materiality recent filing
BiondVax enters exclusive worldwide license for IL-17 NanoAbs from Max Planck and UMG
Exclusive worldwide license to develop and commercialize VHH antibodies (NanoAbs) targeting IL-17 for all indications.
Director George H. Lowell resigns from BiondVax board, stays on Scientific Advisory Board
Resignation from Board effective May 12, 2023; served since 2008.
BiondVax publishes investor presentation on May 4, 2023; no financial results disclosed
Presentation made available on company website and discussed in meetings starting May 4, 2023.
BiondVax receives Nasdaq deficiency notice for minimum equity; deficit of $1.76M vs $2.5M required
Stockholders' deficit of $1.76M as of Dec 31, 2022, below Nasdaq's $2.5M minimum equity requirement.
On May 10, 2023, Mr. George H. Lowell submitted to the board of directors (the “Board”) of BiondVax Pharmaceuticals Ltd. (the “Company”) his resignation from his position as a member of the Board, effective May 12, 2023.
Max materiality 0.60 · Median 0.45 · Most common event other_material